PPARγ ligands and their therapeutic applications: A patent review (2008-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 2, 2015, Pages 175-191

  Takada, Ichiro ^a   Makishima, Makoto ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse effects; Bone; Combinations; Diabetes; Inflammation; Neurological diseases; Nuclear receptors; Selective modulators; Skin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 PHENYL ACRYLIC ACID DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ALPHA SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; AROMATIC COMPOUND; BALAGLITAZONE; CANNABIDIOL; CANNABIGEROL; EFATUTAZONE; FK 614; GLITAZONE DERIVATIVE; GW 544; INT 131; MHY 966; MK 0533; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLPROPIONIC ACID DERIVATIVE; PIOGLITAZONE; RIVOGLITAZONE; ROSIGLITAZONE; SPIROLAXINE; SPIROLAXINE DERIVATIVE; SR 1664; SR 1824; SULFONAMIDE; TOLUENE SULFONIC ACID SALT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; LIGAND;

DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOREGULATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; PATENT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; LIPID METABOLISM; PATENTS AS TOPIC; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84922357724     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.985206     Document Type: Review

References (130)

1. Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 2005;97:177-83
2. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20:1405-28
3. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50
4. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312
5. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 2013;19:557-66
6. He W. PPARγ2 polymorphism and human health. PPAR Res 2009;2009:849538
7. Takada I, Kouzmenko AP, Kato S. PPAR-gamma signaling crosstalk in mesenchymal stem cells. PPAR Res 2010;doi.org/10.1155/2010/341671
8. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-63
9. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15
10. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-6
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
12. Mitka M. FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA 2013;310:2604
13. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
14. FDA requires removal of certain restrictions on the diabetes drug Avandia. FDA News Release. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm [Last accessed 25 November 2013]
15. European Medicines Agency. Assesment report for Avandia. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR0---Summary-for-the-public/human/000268/WC500029109.pdf [Last accessed 17 January 2011]
16. Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803-41
17. Galderma Researh & Development. Novel biaromatic compounds that modulate PPAR-receptors. US0012129;2009
18. Galderma Research & Development. Novel 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof. US0144884; 2010
19. Schmuth M, Jiang YJ, Dubrac S, et al. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008;49:499-509
20. The University of Tokyo. a-Substituted phenylpropionic acid derivatives. WO004341; 2008
21. Miyachi H, Nomura M, Tanase T, et al. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferatoractivated receptor (PPAR) activators: novel human PPARalpha-selective activators. Bioorg Med Chem Lett 2002;12:77-80
22. Kasuga J, Yamasaki D, Ogura K, et al. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. Bioorg Med Chem Lett 2008;18:1110-15
23. Raval P, Jain M, Goswami A, et al. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. Bioorg Med Chem Lett 2011;21:3103-9
24. Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same. WO108602; 2008
25. Kim MK, Chae YN, Kim HS, et al. PAR-1622 is a selective peroxisome proliferator-activated receptor g partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Arch Pharm Res 2009;32:721-7
26. Okayama University. Novel α-substituted propionic derivatives. JP2012041334;2010
27. Ohashi M, Nakagome I, Kasuga J, et al. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistryactivity relationship. Bioorg Med Chem 2012;20:6375-83
28. Sauerberg P, Pettersson I, Jeppesen L, et al. Novel Tricyclic-α-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 2002;45:789-804
29. Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity. WO137105; 2008
30. Takeda Pharmaceutical Co., Ltd. Fused ring compounds as partial agonists of PPAR-gamma. WO099794; 2008
31. Merck & Co., Inc. Novel crystalline salt form of an antidiabetic compound. WO109334; 2008
32. Merck & Co., Inc. Fused aromatic compounds having anti-diabetic activity. WO096564; 2006
33. Acton JJ III, Akiyama TE, Chang CH, et al. Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferatoractivated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 2009;52:3846-54
34. Daiichi Sankyo Co., Ltd. Crystalline forms of thiazolidinedione compound and its manufacturing method. US0160462; 2011
35. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006;25:2304-17
36. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012;118:5403-13
37. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 2013;98:2392-400
38. Lee SY, Hur GY, Jung KH, et al. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 2006;51:297-301
39. Oton AB, Cho BC, Ahn M-J, et al. A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC). American Association for Cancer Research Annual Meeting; 2014. Available from: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=8#.VErgpUvFTNo
40. Serizawa M, Murakami H, Watanabe M, et al. Peroxisome proliferator-activated receptor g agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells. Cancer Sci 2014;105:683-9
41. Vivacell Biotechnology España, S.L. Cannabinoid quinone derivatives. WO117429; 2011
42. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009;5:442-7
43. Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010;466:451-6
44. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a nonagonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477:477-81
45. Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders. WO091134; 2011
46. Metabolic Solutions Development Co., LLC. Novel synthesis for thiazolidinedione compounds. WO021476; 2012
47. Metabolic Solutions Development Co., LLC. Synthesis for thiazolidinedione compounds. WO021467; 2012
48. The University of Sydney. PPAR agonists. WO026658; 2009
49. The University of Sydney. Flavnoid PPAR agonists. WO021467; 2009
50. Salam NK, Huang TH, Kota BP, et al. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 2008;71:57-70
51. Sanofi-Aventis. Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use. US0022603; 2010
52. Keil S, Matter H, Schonafinger K, et al. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR)γ/δ agonists with high potency and in vivo efficacy. ChemMedChem 2011;6:633-53
53. Kindex Therapeutics, LLC. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl) cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods. WO058649; 2012
54. Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012;483:350-4
55. Konda VR, Desai A, Darland G, et al. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PLoS One 2014;9:e87848
56. Koren N, Simsa-Maziel S, Shahar R, et al. Exposure to omega-3 fatty acids at early age accelerate bone growth and improve bone quality. J Nutr Biochem 2014;25:623-33
57. Kowa Co., Ltd. Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-one structure and drugs that comprise same. WO095462; 2010
58. Kowa Co., Ltd. Novel 1-(biphenyl-4-yl-methyl)- 1h-imidazole derivative and pharmaceutical product containing same. WO077712; 2011
59. Kowa Co., Ltd. Novel phenylpyridine derivative and drug containing same. WO124311; 2012
60. Kowa Co., Ltd. Novel 2-pyridone derivative and pharmaceutical product containing same. WO077711; 2011
61. The Regents of the University of California. Inhibition of PPAR gamma expression in preadipocyte cells by oxysterols. WO006087; 2011
62. Kim WK, Meliton V, Amantea CM, et al. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. J Bone Miner Res 2007;22:1711-19
63. ProMD Biotech Co., Ltd. Method for enhancing PPARγ expression. US20130344043; 2013
64. Okuno A, Yoshia T, Ogawa J. Pharmaceutical composition containing PPARgamma agonist. US20090137626; 2009
65. Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011;48:885-93
66. Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011;112:2902-9
67. Wellstat Therapeutics Corp. Combination treatment of metabolic disorders. WO117791; 2007
68. InteKrin Therapeutics, Inc. Combination of PPARγ agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity. WO111078; 2009
69. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
70. Kyle KA, Willett TL, Baggio LL, et al. Differential effects of PPAR-gamma activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011;152:457-67
71. Lanfear D, Higgins L. Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity. US0034380; 2011
72. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-46
73. da Rocha Junior LF, Dantas AT, Duarte AL, et al. PPARγ agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res 2013;2013:519724
74. Cipolletta D, Feuerer M, Li A, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012;486:549-53
75. Klotz L, Burgdorf S, Dani I, et al. The nuclear receptor PPARgamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009;206:2079-89
76. Giuliani International Ltd. PPAR-gamma agonists for the induction of ationic antimicrobial peptide expression as immunoprotective stimulants. WO104557; 2008
77. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009;31:368-76
78. Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor g activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010;107:8772-7
79. La Jolla Institute for Allergy and Immunology. Regulatory T cells and methods of making and using same. WO157394; 2008
80. Wohlfert EA, Nichols FC, Nevius E, et al. Peroxisome proliferator-activated receptor (PPAR) and immunoregulation: enhancement of regulatory T cells through PPAR-dependent and - independent mechanisms. J Immunol 2007;178:4129-35
81. Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat and prevent diseases and disorders. US0216883; 2010
82. Guri AJ, Evans NP, Hontecillas R, et al. T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem 2011;22:812-19
83. Rheinische Friedrich-Wilhelms Universität. PPAR gamma agonists for treating illnesses with pathophysiological participation of TH17 lymphocytes. EP2301539; 2011
84. Cardoz AB. Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a PPAR gamma agonist. WO007673; 2009
85. VanderLaan PA, Reardon CA. The immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res 2005;46:829-38
86. Pulmagen Therapeutics (Inflammation) Ltd. Sulfonamide compounds for the treatment of respiratory disorders. WO076553; 2010
87. Pulmagen Therapeutics (Inflammation) Ltd. Inflammatory disease treatment. WO098801; 2011
88. Inhalated PPAR gamma agonists. Pulmagen Therapeutics. Burnham, Bucks, UK. Available from: http://www.pulmagen.com/ppary.html
89. InteKrin Therapeutics, Inc. PPARγ agonists for treatment of multiple sclerosis. WO120538; 2014
90. Lee DH, Huang H, Choi K, et al. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in dietinduced obese mice. Am J Physiol Endocrinol Metab 2012;302:E552-E60
91. Higgins LS, Mantzoros CS. The Development of INT131 as a selective PPARγ modulator: approach to a safer insulin sensitizer. PPAR Res 2008;2008:936906
92. SmithKline Beecham. PPAR-gamma agonists for improvement of cognitive function in Apoe4 negative patients. US0262047; 2008
93. Poirier J, Miron J, Picard C, et al. Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. Neurobiol Aging 2014;35S2:S3-S10
94. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013;108:21-43
95. Brodbeck J, Balestra ME, Saunders AM, et al. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci USA 2008;105:1343-6
96. Omeros Corp. Compositions and methods for prophylaxis and treatment of addictions. EP2612553; 2013
97. Omeros Corp. Compositions and methods for prophylaxis and treatment of addictions. WO105103; 2010
98. Stopponi S, Somaini L, Cippitelli A, et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011;69:642-9
99. Aestus Therapeutics, Inc. Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma. US0024692; 2014
100. Fujimura T, Sakuma H, Konishi S, et al. FK614, a novel peroxisome proliferator-activated receptor γ modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 2005;99:342-52
101. Aestus Therapuetics and Astellas Pharma signs license deal for novel chronic pain therapeutic. Business Wire. Available from: http://www.businesswire.com/news/home/20100628005490/en/Aestus-Therapeutics-Astellas-Pharma-Sign-License-Deal [Last accessed 28 June 2008]
102. Aestus Theraoeytucs, Inc. Methods of treating neuropathic pain with agonists of PPAR-gamma. WO063842; 2008
103. Churi SB, Abdel-Aleem OS, Tumber KK, et al. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49
104. Maeda T, Kiguchi N, Kobayashi Y, et al. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7
105. Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007;320:1002-12
106. Aestus therapeutics reports positive results in phase II neuropathic pain trial for treatment of post-herpetic neuralgia. Business Wire. Available from: http://www.businesswire.com/news/home/20111213005815/en/Aestus-Therapeutics-Reports-Positive-Results-Phase-II [Last accessed 13 December 2011]
107. Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000;136:609-16
108. Umbert Millet I. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same. WO153373; 2009
109. Avon Products, Inc. Use of eclipta prostrata and other PPAR-gamma inhibitors in cosmetics and compositions thereof. WO156136; 2011
110. Pusan National University Indusrty University. Novel compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor. WO108677; 2012
111. Wiechers JW, Rawlings AV, Garcia C, et al. A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor. Int J Cosmet Sci 2005;27:123-32
112. Park MH, Park JY, Lee HJ, et al. The novel PPARa/g dual agonist MHY 966 modulates UVB-induced skin inflammation by inhibiting NF-kB activity. PLoS One 2013;8:e76820
113. Merz Pharma GmbH & Co. KGaA. Composition comprising peroxisome proliferator-activated receptor-gamma (PPAR). WO117013; 2012
114. Cedars-Sinai Medical Center. Methods of using PPAR-gamma agonists and caspasedependent chemotherapeutic agents for the treatment of cancer. WO008767; 2008
115. Akasaki Y, Liu G, Matundan HH, et al. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006;281:6165-74
116. Wang L, Yu CJ, Liu W, et al. Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin 2011;32:991-8
117. Centre National de la Recherche Scientifique. RXR-PPARgamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer. WO070379; 2010
118. Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:604-15
119. Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. Cell 2014;157:255-66
120. Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of adverse effect due to the use of PPAR-gamma agonists. WO141897; 2008
121. Patano N, Mancini L, Settanni MP, et al. l-Carnitine fumarate and isovaleryl-l-carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimetally induced osteoporosis in pregnant mice. Calcif Tissue Int 2008;82:221-8
122. Santen Pharmaceutical Co., Ltd. Agent for enhancing corneal epithelial barrier function. WO107652; 2009
123. Indiana University Research and Technology Corp. Use of PPAR gamma modulators to treat cystic liver diseases. WO028370; 2010
124. Nagao S, Yamaguchi T. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 2012;5:292-300
125. Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol 2014;143C:207-22
126. Zhang X, Lanter JC, Sui Z. Recent advances in the development of selective androgen receptor modulators. Expert Opin Ther Pat 2009;19:1239-58
127. Yamada S, Makishima M. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators. Trends Pharmacol Sci 2014;35:324-37
128. Choi M, Makishima M. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin Ther Pat 2009;19:593-606
129. Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance. FDA Guidance for Industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf [Last accessed 3 March 2008]
130. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311:1515-25